Moderna, Pfizer and COVID-19

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...
Moderna says its long-running patent dispute with Pfizer and BioNTech isn't over even after a decision by an administrative ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
The police and fire-rescue departments partnered with the town manager’s office to guide the town’s COVID-19 response.
The pandemic's volatility affected all public companies, but some saw their business deeply transformed. Here's how three of ...
Moderna's COVID sales have been declining, and the company has been trimming costs. But it doesn't have a huge growth ...
Mutual of America Capital Management LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.6% during the ...
A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...